IN2014DN08867A - - Google Patents

Info

Publication number
IN2014DN08867A
IN2014DN08867A IN8867DEN2014A IN2014DN08867A IN 2014DN08867 A IN2014DN08867 A IN 2014DN08867A IN 8867DEN2014 A IN8867DEN2014 A IN 8867DEN2014A IN 2014DN08867 A IN2014DN08867 A IN 2014DN08867A
Authority
IN
India
Prior art keywords
present
quinolin
thiophen
piperazin
dihydrate
Prior art date
Application number
Inventor
Hiroshi Yamashita
Tetsuya Sato
Takuya Minowa
Yusuke Hoshika
Hidekazu Toyofuku
Tatsuya Yamaguchi
Masahiro Sota
Shuuji Kawano
Takayuki Nakamura
Ryohei Eto
Takuma Ikebuchi
Kei Moriyama
Nobuaki Ito
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN08867(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of IN2014DN08867A publication Critical patent/IN2014DN08867A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-l-yl)butoxy]- lH-quinolin-2-one or of a salt thereof, and a process for producing the same.
IN8867DEN2014 2012-04-23 2013-04-23 IN2014DN08867A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636920P 2012-04-23 2012-04-23
US201361791378P 2013-03-15 2013-03-15
PCT/JP2013/062681 WO2013162046A1 (en) 2012-04-23 2013-04-23 Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Publications (1)

Publication Number Publication Date
IN2014DN08867A true IN2014DN08867A (en) 2015-05-22

Family

ID=48428584

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8867DEN2014 IN2014DN08867A (en) 2012-04-23 2013-04-23

Country Status (37)

Country Link
US (5) US9499525B2 (en)
EP (1) EP2841431B2 (en)
JP (1) JP5952917B2 (en)
KR (1) KR102160395B1 (en)
CN (1) CN104254530B (en)
AR (1) AR090774A1 (en)
AU (1) AU2013253372B2 (en)
BR (1) BR112014026424B1 (en)
CA (1) CA2870000C (en)
CO (1) CO7111315A2 (en)
CY (1) CY1119103T1 (en)
DK (1) DK2841431T4 (en)
EA (1) EA026541B1 (en)
ES (1) ES2617881T5 (en)
FI (1) FI2841431T4 (en)
HK (1) HK1203073A1 (en)
HR (1) HRP20170242T4 (en)
HU (1) HUE031997T2 (en)
IL (1) IL235044B (en)
IN (1) IN2014DN08867A (en)
JO (1) JO3325B1 (en)
LT (1) LT2841431T (en)
ME (1) ME02619B (en)
MX (1) MX361723B (en)
MY (1) MY170220A (en)
NZ (1) NZ630260A (en)
PH (1) PH12014502324B1 (en)
PL (1) PL2841431T3 (en)
PT (1) PT2841431T (en)
RS (1) RS55742B2 (en)
SG (1) SG11201406790VA (en)
SI (1) SI2841431T2 (en)
SM (1) SMT201700130B (en)
TW (1) TWI562991B (en)
UA (1) UA117456C2 (en)
WO (1) WO2013162046A1 (en)
ZA (1) ZA201407477B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (en) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd Injectable preparation
AR090775A1 (en) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd INJECTABLE PREPARATION
JOP20210047A1 (en) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
US20170042887A1 (en) 2014-04-22 2017-02-16 Otsuka Pharmaceutical. Co., Ltd. Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
CN104447723A (en) * 2014-11-28 2015-03-25 瑞阳制药有限公司 Method for preparing 7-(4-(4-(benzo[b]thienyl)-1-piperazinyl) butoxy)-2(1H)-quinolinone
CN104829603A (en) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 Crystal form A brexpiprazole hydrochloride and preparation method thereof
CN106883223B (en) * 2015-12-16 2021-11-23 北京福元医药股份有限公司 Purification method of Brexpiprazole hydrochloride
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
JP2019059672A (en) * 2015-12-28 2019-04-18 大日本住友製薬株式会社 Agent for treating refractory depression and the like
WO2017115287A1 (en) 2015-12-28 2017-07-06 Honour (R&D) Process for the preparation of quinoline-2(1h)-one derivatives
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (en) 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 One kind is according to piperazine azoles novel crystal forms and preparation method thereof
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
CN106188023A (en) * 2016-07-04 2016-12-07 山东川成医药股份有限公司 A kind of process for purification of epirizole group
PL233778B1 (en) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Method for producing brexpiprazole, intermediate compounds used in this method and method for producing them
WO2018033483A1 (en) 2016-08-16 2018-02-22 H E X A L Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
EP3500247B1 (en) 2016-08-16 2020-05-27 H e x a l Aktiengesellschaft Immediate release tablet of a benzothiophene compound
CN107936005A (en) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 One kind is according to piperazine azoles novel crystal forms II and preparation method thereof
CN106699745A (en) * 2016-12-14 2017-05-24 上海博志研新药物技术有限公司 Brexpiprazole methyl alcohol compound, crystal form A and preparation method and application
EP3577111A1 (en) 2017-02-02 2019-12-11 Hexal Aktiengesellschaft Crystalline brexpiprazole
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
CN111440158A (en) * 2020-03-24 2020-07-24 石药集团中奇制药技术（石家庄）有限公司 Novel crystal form of brexpiprazole hydrochloride and preparation method thereof
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (en) * 2021-02-16 2022-08-25 大塚製薬株式会社 Amorphous material and composition containing said amorphous material
WO2023067664A1 (en) * 2021-10-18 2023-04-27 大塚製薬株式会社 Novel crystal form of benzothiophene compound and production method therefor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (en) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME
JP4836797B2 (en) † 2003-10-23 2011-12-14 大塚製薬株式会社 Controlled release sterile injection aripiprazole formulations and methods
US20090198059A1 (en) 2004-09-13 2009-08-06 Chava Satyanarayana Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts
DE102005001989A1 (en) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenous formulations of PDE inhibitors
JP4315393B2 (en) 2005-04-14 2009-08-19 大塚製薬株式会社 Heterocyclic compounds
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
PE20090387A1 (en) * 2007-05-24 2009-04-28 Novartis Ag PASSIREOTY FORMULATION
AU2008316667A1 (en) * 2007-10-26 2009-04-30 Repligen Corporation Methods of identifying histone deacetylase inhibitors useful for neurological disorders
US20110003002A1 (en) * 2008-01-30 2011-01-06 Holger Petersen Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
WO2012026562A1 (en) † 2010-08-24 2012-03-01 Otsuka Pharmaceutical Co., Ltd. Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
JP2012232958A (en) * 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd Injection preparation
KR101911121B1 (en) * 2011-07-28 2018-10-23 오쓰까 세이야꾸 가부시키가이샤 Method for producing benzo[b]thiophene compound
JO3227B1 (en) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd Piperazine-substituted benzothiophene deriveatives as antipsychotic agents
AR090775A1 (en) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd INJECTABLE PREPARATION
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (en) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd Injectable preparation

Also Published As

Publication number Publication date
US20210115030A1 (en) 2021-04-22
BR112014026424A2 (en) 2017-06-27
MY170220A (en) 2019-07-10
PH12014502324A1 (en) 2015-01-12
RS55742B2 (en) 2024-04-30
HRP20170242T4 (en) 2024-03-01
ME02619B (en) 2017-06-20
DK2841431T4 (en) 2024-02-12
ES2617881T5 (en) 2024-05-22
US9499525B2 (en) 2016-11-22
CA2870000A1 (en) 2013-10-31
PH12014502324B1 (en) 2015-01-12
CA2870000C (en) 2021-02-16
HRP20170242T8 (en) 2017-09-22
AU2013253372B2 (en) 2016-12-08
MX2014012527A (en) 2015-03-19
SI2841431T1 (en) 2017-03-31
PT2841431T (en) 2017-03-07
CO7111315A2 (en) 2014-11-10
SMT201700130B (en) 2017-03-08
EA026541B1 (en) 2017-04-28
AR090774A1 (en) 2014-12-03
US10407415B2 (en) 2019-09-10
SI2841431T2 (en) 2024-03-29
SG11201406790VA (en) 2014-11-27
RS55742B1 (en) 2017-07-31
PL2841431T3 (en) 2017-06-30
CN104254530A (en) 2014-12-31
LT2841431T (en) 2017-03-27
TWI562991B (en) 2016-12-21
FI2841431T4 (en) 2024-04-18
AU2013253372A1 (en) 2014-10-30
HRP20170242T1 (en) 2017-04-07
DK2841431T3 (en) 2017-03-06
HK1203073A1 (en) 2015-10-16
IL235044A0 (en) 2014-12-31
BR112014026424B1 (en) 2022-09-13
HUE031997T2 (en) 2017-08-28
EP2841431A1 (en) 2015-03-04
EP2841431B2 (en) 2024-01-24
CN104254530B (en) 2016-09-21
US20230049327A1 (en) 2023-02-16
IL235044B (en) 2019-05-30
TW201348229A (en) 2013-12-01
NZ630260A (en) 2015-09-25
JO3325B1 (en) 2019-03-13
WO2013162046A1 (en) 2013-10-31
KR20150013189A (en) 2015-02-04
US20170066752A1 (en) 2017-03-09
EA201491933A1 (en) 2015-03-31
KR102160395B1 (en) 2020-09-28
ZA201407477B (en) 2015-12-23
CY1119103T1 (en) 2018-02-14
JP2015514677A (en) 2015-05-21
EP2841431B1 (en) 2017-01-04
JP5952917B2 (en) 2016-07-13
US20200140424A1 (en) 2020-05-07
ES2617881T3 (en) 2017-06-20
US20150087655A1 (en) 2015-03-26
MX361723B (en) 2018-12-14
UA117456C2 (en) 2018-08-10

Similar Documents

Publication Publication Date Title
IN2014DN08867A (en)
IN2015DN01156A (en)
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
PH12014502496B1 (en) Bicyclically substituted uracils and the use thereof
MY180751A (en) 3,4-dihydroisoquinolin-2(1h)-yl compounds
MX2016000794A (en) High potency pancreatin pharmaceutical compositions.
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
NZ749557A (en) 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides
MX2016006975A (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases.
MX2016000480A (en) High potency pancreatin pharmaceutical compositions.
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
TN2014000532A1 (en) N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
MX2014007364A (en) Novel heterocyclic carboxamides as modulators of kinase activity.
PH12015500322A1 (en) Tris(hetero)arylpyrazoles and use thereof
IN2014DN10683A (en)
MX2013002446A (en) Substituted tetrahydropyrrolopyrazine derivatives.
TN2014000085A1 (en) Substituted annellated pyrimidine and the use thereof
IN2013MU03838A (en)